PCV13

PCV13

An abbreviation for a pneumococcal polyvalent vaccine composed of 13 capsular antigens of Streptococcus pneumoniae. It is used, like PCV7, to immunize children against pneumococcal diseases, e.g., otitis media, pneumonia, meningitis.
References in periodicals archive ?
The ACIP provisional recommendations also say that a single dose of PCV13 may be administered to children ages 6 to 18 years who are at increased risk for IPD because of sickle cell disease, HIV infection or other immunocompromising condition, cochlear implant, or cerebrospinal fluid leaks, regardless of whether they have previously received PCV7 or PPSV237 This, however, is an off-label recommendation.
Recently, the ACIP recommended routine administration of both PCV13 and PPSV23 to all adults [greater than or equal to] 65 years of age (5).
Pneumococcal conjugate vaccine for children compatible with PCV13 vaccine - to continue vaccinationThe size of the purchase of 95 800 dosesDelivery dates And delivery - 25 800 doses - until 30.
Key clinical point: Preterm infants have a lower initial immune response to PCV13 that increases after the toddler booster dose.
In the report, "Declines in Pneumonia Hospitalizations of Children Aged <2 Years Associated with the Use of Pneumococcal Conjugate Vaccines--Tennessee, 1998-2012," in Table 2, under the heading and subheading PCV13 years compared with pre-PCV7 years [[dagger]], % change in rates, the value should read, -72.
The inclusion of the older pediatric age group will harmonize the PCV13 pediatric recommendation and may improve vaccine uptake in these groups, Tamara Pilishvili, M.
At its meeting this month, the Advisory Committee on Immunization Practices reviewed the evidence for the use of PCV13 in adults aged 65 years and older and in immunocompromised adults.
ACIP will make recommendations on how to introduce PCV13 into a schedule for infants and children who are in the middle of a PCV7 series, and for catch-up vaccination for children who have completed a PCV7 series.
This study highlights the high potential for reduction of IPD among children after introduction of PCV13 in Cambodia; 88.
Pneumococcal conjugate vaccine for children compatible with PCV13 vaccine - to continue vaccination, the number of doses of 8090 with delivery within 10 days of the conclusion of the contract for performance of the contract.
The results showed that PCV7 and PCV13 vaccinations led to significant decreases in sinusitis and pneumonia cases for children at or under the age of 2, while a decrease, though less profound, was also noted in cases of sinusitis and pneumonia for children between 2 and 5 years of age.
To examine changes in all-cause pneumonia hospitalizations among children aged <2 years after the switch to PCV13, Tennessee hospital discharge data for 1998-2012 were analyzed.